2018
Transparency and Dermatologic Device Approval by the US Food and Drug Administration
Ezaldein HH, Scott JF, Yin ES, Ventura A, DeRuyter NP, Leffell DJ. Transparency and Dermatologic Device Approval by the US Food and Drug Administration. JAMA Dermatology 2018, 154: 273-280. PMID: 29365020, PMCID: PMC5885836, DOI: 10.1001/jamadermatol.2017.5757.Peer-Reviewed Original Research
2003
Complications in Dermatologic Surgery: How Safe Is Safe?
Aasi SZ, Leffell DJ. Complications in Dermatologic Surgery: How Safe Is Safe? JAMA Dermatology 2003, 139: 213-214. PMID: 12588228, DOI: 10.1001/archderm.139.2.213.Peer-Reviewed Original Research
1993
Nonexcisional Treatment of Benign and Premalignant Cutaneous Lesions
Morganroth G, Leffell D. Nonexcisional Treatment of Benign and Premalignant Cutaneous Lesions. Clinics In Plastic Surgery 1993, 20: 91-104. PMID: 8420713, DOI: 10.1016/s0094-1298(20)30775-6.Peer-Reviewed Original Research
1992
Lasers in Dermatology and Ophthalmology
Leffell D, Thompson J. Lasers in Dermatology and Ophthalmology. Dermatologic Clinics 1992, 10: 687-700. PMID: 1395152, DOI: 10.1016/s0733-8635(18)30305-x.Peer-Reviewed Original ResearchMeSH KeywordsEye DiseasesEye NeoplasmsHemangiomaHumansLaser TherapyLight CoagulationRetinaSkin DiseasesSkin NeoplasmsConceptsVascular retinal diseasesOpen-angle glaucomaSpecific disease processesPort-wine stainsMacular edemaClosure glaucomaAngle glaucomaIntraocular tumorsNeoplastic lesionsAdnexal tumorsDisease processRetinal diseasesLaser treatmentDermatologyWine stainsGlaucomaOphthalmologyTumorsTreatmentUse of lasers